News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
689,838 Results
Type
Article (41076)
Company Profile (332)
Press Release (648430)
Section
Business (207358)
Career Advice (1970)
Deals (35907)
Drug Delivery (81)
Drug Development (82938)
Employer Resources (168)
FDA (16156)
Job Trends (14992)
News (350199)
Policy (32925)
Tag
Academia (2615)
Africa (726)
Alabama (32)
Allergies (38)
Alliances (50377)
Alzheimer's disease (1134)
Antibody-drug conjugate (ADC) (48)
Approvals (16096)
Arizona (167)
Artificial intelligence (51)
Asia (37950)
Australia (6285)
Bankruptcy (359)
Best Places to Work (11363)
Biosimilars (56)
C2C Services and Suppliers (79644)
California (830)
Canada (643)
Cancer (187)
Career advice (1647)
CAR-T (36)
Cell therapy (73)
China (49)
Clinical research (64314)
Collaboration (63)
Colorado (35)
COVID-19 (2510)
Cystic fibrosis (73)
Diabetes (34)
Diagnostics (5944)
Diversity, equity & inclusion (44)
Drug pricing (54)
Earnings (83966)
Employer resources (142)
Europe (82516)
Events (110277)
FDA (16199)
Florida (106)
Funding (40)
Gene therapy (61)
GLP-1 (495)
Government (4351)
Healthcare (18855)
Hotbed/Location (488379)
Idaho (55)
Illinois (198)
Indiana (107)
Infectious disease (2523)
Inflammatory bowel disease (89)
Interviews (305)
IPO (16389)
Job creations (3686)
Job search strategy (1421)
Kansas (92)
Layoffs (397)
Legal (7888)
Liver cancer (52)
Lung cancer (40)
Maine (47)
Management (53)
Manufacturing (46)
Maryland (257)
Massachusetts (456)
Medical device (13088)
Medtech (13091)
Mergers & acquisitions (19209)
Metabolic disorders (167)
Neuroscience (1216)
New Jersey (62)
New York (84)
NextGen Class of 2024 (6670)
Non-profit (4508)
North Carolina (167)
Obesity (109)
Opinion (179)
Patents (33)
Peanut (34)
Pennsylvania (56)
People (56873)
Phase I (20119)
Phase II (28389)
Phase III (21054)
Podcasts (33)
Policy (36)
Postmarket research (2582)
Preclinical (8657)
Rare diseases (94)
Real estate (5983)
Recruiting (64)
Regulatory (21432)
Reports (32)
Research institute (2389)
Resumes & cover letters (345)
South America (1099)
Startups (3732)
Texas (87)
United States (3060)
Vaccines (422)
Washington State (114)
Weight loss (105)
Date
Today (12)
Last 7 days (504)
Last 30 days (1831)
Last 365 days (39329)
2024 (22314)
2023 (41018)
2022 (52277)
2021 (56767)
2020 (54929)
2019 (47425)
2018 (35706)
2017 (33036)
2016 (32353)
2015 (38401)
2014 (32190)
2013 (27116)
2012 (29221)
2011 (29868)
2010 (27998)
689,838 Results for "dmd therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
REGENXBIO to Participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
March 27, 2024
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
3 min read
·
Voyager Therapeutics, Inc.
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Catalyst Pharmaceuticals, Inc. today announced the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy (“DMD”) in patients aged two years and older.
March 13, 2024
·
7 min read
FDA
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age.
June 20, 2024
·
12 min read
FDA
Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy
On the heels of a Phase III flop for Pfizer’s Duchenne muscular dystrophy gene therapy candidate, the FDA has green lighted the expanded use of Sarepta Therapeutics’ Elevidys.
June 20, 2024
·
6 min read
·
Tyler Patchen
Biotech Beach
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel (CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD).
June 25, 2024
·
5 min read
Genetown
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
Dyne Therapeutics, Inc. announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
May 20, 2024
·
16 min read
FDA
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients
While Thursday’s label expansion and traditional approval for the gene therapy is an important milestone, many challenges still face the Duchenne muscular dystrophy community.
June 21, 2024
·
3 min read
·
Greg Slabodkin
Drug Development
Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology
Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6 years of age and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology.
March 19, 2024
·
7 min read
FDA
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
As Sarepta Therapeutics moves closer to full approval and an expanded label for its gene therapy, some experts push back on clinical efficacy and cost while others note the hope it provides patients with Duchenne muscular dystrophy.
May 7, 2024
·
4 min read
·
Tyler Patchen
1 of 68,984
Next